Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease ...Middle East

Data from the trial is expected to be shared in 2025 LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease )

Also on site :

• Harris Dickinson On The Inspiration For Cannes Directing Debut ‘Urchin’ And Why Upcoming John Lennon Role Is His “Every Day Right Now”
• Pursuit of stolen car ends with suspect crashing in North Highlands
• Podcaster Calls for 'Trigger Warning' After Cassie's Violent Testimony